AbbVie boosts oncology exposure with $21bn deal for Pharmacyclics.
Datamonitor Healthcare explores the rationales behind AbbVie’s acquisition of Pharmacyclics
By Ali Al-Bazergan, Lead Analyst
6 March 2015
I am the Lead Analyst of the company analysis team at Datamonitor Healthcare, based in the London office. I focus on tra...
Read full bio
On 5 March 2015, AbbVie announced its $21bn cash and equity offer for biotechnology firm Pharmacyclics after a three-way competitive bidding war. The deal provides AbbVie with access to Pharmacyclics’s sole marketed oncology drug Imbruvica. AbbVie has touted the drug as a “pipeline in a molecule,” drawing comparisons to flagship immunology drug Humira by creating leadership in a lucrative market setting.
Join Senior Analyst, Ali Al-Bazergan as he explores the rationale and potential implications behind the biggest deal of 2015 to date.
You can also read Ali’s initial opinion on the deal by clicking here >>
Posted in Company analysis.